STENOCARE Aktie

 

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO Annual general meeting On 15 May 2025 annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the annual report together with a resolution for its adoption 4. Resolution to appropriate the profit or cover the loss 5. Election of members of the board of...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2025 – 31.03.2025. The report, which has not been reviewed by the Company's auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” The Company has truly entered the new STENOCARE 3.0 phase, built around a strong trading platform, high-quality products, and sufficient liquidity to execute our growth strategy.” [] (KDKK) 01....

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) is pleased to announce that the Danish Parliament has officially passed legislation to make Denmark's medical cannabis program permanent. The new law, which takes effect on January 1, 2026, marks a significant step forward in securing long-term access to medical cannabis treatment for patients and providing regulatory stability for the Stenocare business in Denmark. Since 2018, Denmark has operated a Pilot Programme for medical cannabis, which is scheduled to expire in December 2025....

STENOCARE A/S Nasdaq First North Growth Market, Denmark Ticker: STENO The board of directors hereby convenes the shareholders of STENOCARE to the Annual General Meeting, which will be held: STENOCARE A/S 15 May 2025 at 10:00 AM (CEST) (the doors open at 9:30 AM)                                   at Lund Elmer Sandager Law Firm Kalvebod Brygge 39-41 DK-1560 København V With the following agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the audited annual report together with a resolution for...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) and its local partner have successfully secured approval for the reimbursement of the innovative ASTRUM 10-10 product by major German health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10. The ASTRUM 10-10 oil product was made available to German patients in January 2025 and has now been approved for 100% reimbursement by two leading German health insurance providers, Techniker...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) participated in a video-recorded interview with Proinvestor.com to discuss the Annual Report for 2024. The Stenocare CEO and CFO are answering questions from Proinvestor Editor, Helge Larsen. Stenocare published the Annual Report 2024 on March 27 which is available on the company investor page. The Stenocare CEO and CFO both participated in an interview with Proinvestor.com to comments on the results, the new STENOCARE 3.0 strategy and the capital raise that all had an impact on the...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO The Board of Directors and the Chief Executive Officer of STENOCARE A/S (“STENOCARE”) hereby publish the annual report for the fiscal year 2024. The annual report, including the auditor's report, is available as an attached file and on STENOCARE's website (https://stenocare.com/investor-relations/) and Nasdaq First North (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=CSE196164). Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “We reached an important milestone and exceeded our updated...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2024 – 31.12.2024. The report, which has not been reviewed by the Company's auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”Stenocare initiated a capital raise to execute the new STENOCARE 3.0 strategy, positioning the company strongly for future opportunities. Sales exceeded the updated 2024 guidance, and operating profit...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the “Company”) announced November 26, 2024, the new STENOCARE 3.0 strategy to transform into a leading trading company with medical cannabis products. With the successful completion of the Rights Issue in January 2025, Stenocare is now exiting the cultivation facility and relocating its HQ address to the Copenhagen facility. This will also result in significant costs reductions in 2025 and beyond. The STENOCARE 3.0 strategy, unveiled on November 26, 2024, position the company as a...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on January 22, 2025. The subscription period in the Conditional Rights Issue (“Rights Issue” or “Issue”) of STENOCARE A/S (“Stenocare” or the “Company”) ended on 20 January 2025. The Rights Issue was subscribed to approximately 37.7 percent, equivalent to 15,229,927 new shares, including the pre-subscription commitments...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") has final deadline today for investors to subscribe for new shares at a discounted price of DKK 0.50 each. The final deadline for this time limited offer is January 20, 2025 at 5:00 PM Copenhagen time, and investors should decide if they like to subscribe using the online subscription form (https://stenocare.com/wp-content/uploads/2025/01/Subscription-Form-ENG.pdf) or use any subscription rights they own. Stenocare has announced a time limited offer to subscribe for new...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. The final deadline for this time limited offer is January 20, 2025, and owners of subscription rights should decide how to use these rights and new investors should decide if they like to subscribe using the online subscription form (https://stenocare.com/wp-content/uploads/2025/01/Subscription-Form-ENG.pdf). Stenocare has announced a time limited...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) reach another important milestone with ASTRUM 10-10, that is now ready for sales to German patients. The innovative and patented medical cannabis oil product, ASTRUM 10-10 has the potential to improve uptake in the blood and thereby improve efficacy of the treatment. Stenocare new innovative medical cannabis oil product named Astrum 10-10 has been approved for sales in Germany and is now ready for patient's treatment. Officially named “Astrum 10-10 Oil Stenocare,” the product contains 10...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 – however some banks have a shorter deadline with deadline around January 15. Shareholders and new investors interested in this offer should check the deadline with their bank. Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of DKK 0.50...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the “Company”) announces that the Company has received a legally binding guarantee commitment of 2 mDKK from Exelity AB, securing approximately 9.9 percent of the total issue corresponding to approximately 22.0 percent of the minimum subscription. As stated in the announcement of 18 December 2024, the Company has also received legally binding written pre-subscription commitments and compensation-free guarantees from management and existing shareholders of 1.5 mDKK, corresponding to...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 – however some banks, including Nordnet, have a shorter deadline on Monday January 13. Shareholders and new investors interested in this offer should check the deadline with their bank. Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Today, January 7, 2025, the subscription period in STENOCARE A/S' ("Stenocare" or the "Company") rights issue begins. The last day of the subscription...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) reaches an important milestone with ASTRUM 10-10, which is now ready for sale to Norwegian patients. The innovative and patented medical cannabis oil product, ASTRUM 10-10, has the potential to improve uptake in the blood and thereby enhance the efficacy of the treatment. Stenocare announced on December 2, 2024, that the new innovative medical cannabis oil product, named Astrum 10-10, has been approved for sale in Norway. At the end of December, the first shipment of this product arrived...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board of Directors in STENOCARE A/S (“Stenocare” or the “Company”) has today resolved to increase the share capital of Stenocare with up to a...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO Extraordinary general meeting On 18 December 2024 an extraordinary general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39 -41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Election of members of the board of directors 3. Authorisation to the board of directors 4. Amendment of articles of association 5. Any other business Re. 1                   Appointment of a chairman...